BeOne Medicines (ONC) opened 2026 with Q1 revenue of US$1.5b and basic EPS of US$2.05, alongside net income of US$227.4 million. This sets a clear marker for how the business is currently converting its top line into earnings. Over the past year, the company has seen quarterly revenue move from US$1.1b in Q1 2025 to US$1.5b in Q1 2026, while basic EPS shifted from essentially flat at US$0.01 to US$2.05. This gives investors a straightforward read on how profitability is tracking against the recent growth story. The overall picture is one of firmer margins coming through in the reported numbers, which puts the focus squarely on how durable this earnings profile might be.

See our full analysis for BeOne Medicines.

With the latest figures on the table, the next step is to line these results up against the dominant market narratives around growth, risk, and profitability to see which views hold up and which may need a rethink.

Profitability now running at US$513m over the last year

• On a trailing 12 month basis, BeOne Medicines reports net income of US$513.0m on US$5.7b of revenue, compared with a trailing loss of US$644.8m on US$3.8b of revenue just five quarters ago.
• What stands out for the bullish narrative is that this move into profit lines up with the view that strong drug performance and global expansion can support higher margins, yet:
  • Trailing basic EPS has swung to US$4.66 from a loss of US$6.12 per share five quarters earlier, which heavily supports the bullish claim that the business has crossed an important profitability milestone.
  • At the same time, the bullish view assumes margins can rise further. The current US$513.0m of trailing net income therefore becomes a reference point for assessing whether that optimism about future earnings is already reflected in today’s share price.

Bulls argue this profit shift is just the beginning. If you want to see how they connect the recent numbers to a longer term story, check out the 🐂 BeOne Medicines Bull Case.

High growth forecasts meet a 67.9x P/E

• Forecasts in the data point to about 30.5% yearly earnings growth and 11.7% yearly revenue growth, while the stock is shown trading on a trailing P/E of roughly 67.9x compared with about 32.5x for peers and 17.6x for the wider US biotech group.
• Critics in the bearish narrative focus on this gap, arguing that reliance on a single oncology drug and competitive pressure could make that premium hard to justify:
  • The same dataset flags that BeOne only recently became profitable, so the current 67.9x multiple is being placed on a still developing earnings base rather than a long history of stable profits.
  • Bears also point out that although analysts indicate upside to a US$408.54 price target from the current US$313.32 share price, a rich P/E versus peers leaves little room for disappointment if growth or pricing comes under pressure.

Skeptics think this valuation leaves little room for error. If you want to see how they build that case around the same figures, take a look at the 🐻 BeOne Medicines Bear Case.

DCF fair value and targets outpace US$313 share price

• The analysis data show a DCF fair value of about US$803.95 and an analyst consensus price target of US$408.54, both above the current share price of US$313.32, while the company is flagged as having high quality earnings over the last year.
• Consensus narrative supporters highlight this gap between modeled value and price, but the trailing numbers also introduce some tension with that view:
  • On one hand, trailing revenue of US$5.7b and net income of US$513.0m support the idea that the company is no longer in heavy loss making mode, which aligns with the high quality earnings label in the data.
  • On the other hand, the combination of a 67.9x P/E and a share price still below both the DCF fair value and the US$408.54 target means investors need to weigh whether those models are too optimistic or the market is discounting the forecast growth and profitability outlined in the narratives.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BeOne Medicines on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given how mixed the sentiment around BeOne Medicines can feel, it makes sense to move quickly and review the underlying data yourself so your view is grounded in facts rather than headlines. To see what the data is flagging as potential upside, take a closer look at the 4 key rewards.

See What Else Is Out There

For all the progress in profitability, BeOne Medicines still carries a rich 67.9x P/E on a relatively short track record of positive earnings, which leaves limited room for disappointment.

If that premium multiple makes you cautious, compare this setup with companies screened as having stronger value support using the 45 high quality undervalued stocks now and see how they stack up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.